KRTX - What's in store for biotech M&A and IPOs in 2024?
2024-01-01 15:37:15 ET
More on AbbVie, Bristol-Myers Squibb Company , etc.
- Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation
- Bristol Myers Squibb: Too Many Headwinds To Ignore, Despite The Stellar Management
- Bristol Myers Squibb: Aggressive M&A, A Riskier Strategy To Fix The Growth Challenge
- Pharma and biotech deal values spike 35% in 2023: report
- FDA’s new drug approvals for 2023 rise 51% from last year
For further details see:
What's in store for biotech M&A and IPOs in 2024?